JAC Advance Access originally published online on May 30, 2006
Journal of Antimicrobial Chemotherapy 2006 58(2):418-422; doi:10.1093/jac/dkl184
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe
1 Department of General Practice, University of Antwerp Antwerp, Belgium 2 Fund for Scientific Research—Flanders Brussels, Belgium 3 Laboratory of Microbiology, University of Antwerp Antwerp, Belgium 4 Unit of Epidemiology, Scientific Institute of Public Health Brussels, Belgium 5 Laboratory of Microbiology, Leiden University Medical Center Leiden, The Netherlands
Received 21 December 2005; returned 17 February 2006; revised 12 April 2006; accepted 16 April 2006
*Correspondence address. Laboratory of Microbiology, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium. Tel: +32-3-820-2751; Fax: +32-3-820-2752; E-mail: samuel.coenen{at}ua.ac.be
Background: Data on outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe were collected from 25 countries within the ESAC project, funded by DG SANCO of the European Commission, using the WHO ATC/DDD methodology.
Methods: For the period 1997–2003, data on outpatient use of systemic MLS aggregated at the level of the active substance were collected and expressed in DDD (WHO, version 2004) per 1000 inhabitants per day (DID). Macrolide use was analysed in detail, using a classification based on their mean plasma elimination half-life.
Results: Total outpatient MLS use in 2003 varied by a factor of 11 between the country with the highest (9.36 DID in Greece) and lowest (0.85 DID in Sweden) use. MLS use showed high seasonal variation. Short-, intermediate- and long-acting macrolides were used most in 6, 18 and 1 countries, respectively (mainly erythromycin, clarithromyin and azithromycin, respectively). Lincosamide use was observed in all countries (mainly clindamycin) and substantial streptogramin use only in France (pristinamycin). From 1997 to 2003, MLS use increased in 14 countries and was most pronounced in Greece (increase of >5 DID). Except for Sweden, a relative increase of intermediate- (mainly clarithromycin) and/or long-acting (mainly azithromycin) macrolide use was observed, at the expense of short-acting macrolide (mainly erythromycin) use.
Conclusion: The observed differences between European countries in the levels of MLS use and the extreme seasonal variations in their use suggest that this class of antibiotics is prescribed inappropriately in many countries. The MLS classification developed here facilitates a more comprehensive description of macrolide use in Europe. These data (collected as part of ESAC) could promote investigations that lead to a deeper understanding of the link between macrolide use and resistance.
Keywords: antibiotic use , macrolides , drug consumption , pharmacoepidemiology , ambulatory care , Europe
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. K. Glass, D. L. Pearl, S. A. McEwen, and R. Finley Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006) J. Antimicrob. Chemother., October 28, 2009; (2009) dkp391v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Coenen, A. Muller, N. Adriaenssens, V. Vankerckhoven, E. Hendrickx, H. Goossens, and on behalf of the ESAC Project Group European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe J. Antimicrob. Chemother., July 1, 2009; 64(1): 200 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dong, H. Yan, and D. Wang Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China J. Antimicrob. Chemother., August 1, 2008; 62(2): 410 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Richter, K. P. Heilmann, C. L. Dohrn, S. E. Beekmann, F. Riahi, J. Garcia-de-Lomas, M. Ferech, H. Goossens, and G. V. Doern Increasing telithromycin resistance among Streptococcus pyogenes in Europe J. Antimicrob. Chemother., March 1, 2008; 61(3): 603 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Denton, B. O'Connell, P. Bernard, V. Jarlier, Z. Williams, and A. S. Henriksen The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland J. Antimicrob. Chemother., March 1, 2008; 61(3): 586 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Flamaing, J. Verhaegen, J. Vandeven, N. Verbiest, and W. E. Peetermans Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era J. Antimicrob. Chemother., January 1, 2008; 61(1): 143 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Coenen, M. Ferech, F. M Haaijer-Ruskamp, C. C Butler, R. H Vander Stichele, T. J M Verheij, D. L Monnet, P. Little, H. Goossens, and the ESAC Project Group European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe Qual. Saf. Health Care, December 1, 2007; 16(6): 440 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Euler, P. A. Ryan, J. M. Martin, and V. A. Fischetti M.SpyI, a DNA Methyltransferase Encoded on a mefA Chimeric Element, Modifies the Genome of Streptococcus pyogenes J. Bacteriol., February 1, 2007; 189(3): 1044 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ferech, S. Coenen, S. Malhotra-Kumar, K. Dvorakova, E. Hendrickx, C. Suetens, H. Goossens, and on behalf of the ESAC Project Group European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe J. Antimicrob. Chemother., August 1, 2006; 58(2): 401 - 407. [Abstract] [Full Text] [PDF]
|
|